Define thyroid disorder
Reading File
Finding Sources
Searching the Web
thyroid disorder definition classification overview
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive textbook content. Here is the full answer:
Thyroid Disorder - Definition and Overview
A thyroid disorder is any medical condition that disrupts the normal structure or function of the thyroid gland, resulting in the gland producing too much hormone, too little hormone, or developing structural abnormalities (such as nodules or enlargement) that may or may not affect hormone output. The thyroid gland - a butterfly-shaped gland in the anterior neck - normally secretes thyroxine (T4) and triiodothyronine (T3), which regulate metabolism, growth, thermogenesis, heart rate, and homeostasis throughout the body. When this is disrupted, systemic effects follow.
The Two Main Functional Categories
1. Hypothyroidism (Underactive Thyroid)
Hypothyroidism is a hypometabolic state resulting from circulating thyroid hormone levels insufficient to meet the body's requirements. Serum TSH is typically >10 mIU/L (and can exceed 25 mIU/L in prolonged cases).
Common Causes:
- Autoimmune disease - primarily Hashimoto thyroiditis (most common cause in the US)
- Insufficient dietary iodine intake
- Thyroid surgery or radiation exposure (head/neck)
- Viral infection
- Central (secondary) disease - pituitary failure
Symptoms and Signs:
| Feature | Hypothyroidism |
|---|---|
| Symptoms | Fatigue, cold sensitivity, weight gain, dry skin/hair/nails, constipation, muscle weakness, depression |
| Signs | Puffy facies, macroglossia, bradycardia, hypermenorrhea, delayed deep tendon reflex relaxation, hypercholesterolemia, generalized non-pitting edema |
| Lab Findings | Low free T4, elevated TSH |
2. Hyperthyroidism (Overactive Thyroid)
Hyperthyroidism is a biochemical state characterized by increased thyroid hormone biosynthesis and secretion, producing a hypermetabolic syndrome. It is diagnosed by sTSH <0.1 mIU/L with elevated free T4 and/or T3.
Common Causes:
- Graves disease - most common; caused by TSH receptor-stimulating antibodies (TSH-RS Abs) that mimic TSH, driving excess T4 production
- Toxic multinodular goiter (Plummer disease)
- Autonomous functioning (toxic) nodule
- Acute thyroiditis
- TSH-producing pituitary adenoma
- Factitious disorder (excess exogenous thyroid hormone)
Symptoms and Signs:
| Feature | Hyperthyroidism |
|---|---|
| Symptoms | Nervousness/irritability, heat intolerance, palpitations, weight loss, diarrhea, insomnia, weakness |
| Signs | Thyromegaly with or without thyroid bruit, tachycardia, sweating, tremor, hyperactive deep tendon reflexes, exophthalmos (in Graves disease), pretibial myxedema (in Graves disease) |
| Lab Findings | Elevated free T4 and/or T3, low/suppressed TSH |
Thyroid Storm (Severe Complication)
Thyroid storm is a life-threatening variant of thyrotoxicosis in which the hypermetabolic state is severe enough to cause multi-organ failure. It is a clinical diagnosis - not defined by T4 or TSH levels. Key features include:
- Hyperpyrexia (>102°F / 38.9°C)
- Tachycardia disproportionate to temperature
- GI dysfunction: nausea, vomiting, diarrhea, jaundice
- CNS dysfunction: hyperirritability, anxiety, confusion, coma
Mortality can reach 75% if unrecognized. Any patient with goiter, fever, and marked tachycardia should be treated as thyroid storm until proven otherwise.
Other Thyroid Disorders
Beyond functional abnormalities, thyroid disorders also include:
| Type | Examples |
|---|---|
| Structural | Goiter (diffuse enlargement), thyroid nodules, thyroid cysts |
| Autoimmune | Hashimoto thyroiditis (hypothyroid), Graves disease (hyperthyroid) |
| Inflammatory | Subacute thyroiditis (de Quervain), postpartum thyroiditis |
| Neoplastic | Papillary thyroid cancer (most common), follicular, medullary, anaplastic carcinoma |
| Congenital | Cretinism (congenital hypothyroidism due to iodine deficiency) |
| Subclinical | Subclinical hypothyroidism (elevated TSH, normal T4) or subclinical hyperthyroidism (suppressed TSH, normal T4) - no overt symptoms but risk of progression |
Thyroid Hormone Metabolism (Overview)
T4 and T3 are produced in thyroid follicular cells through a pathway dependent on iodide uptake. Both are bound to thyroglobulin (Tg) in the colloid, then released into the bloodstream. T4 is the main secretory product; T3 (the biologically active form) is largely produced by peripheral deiodination of T4.
Drugs that can induce thyroid disorders include amiodarone (can cause both hypo- and hyperthyroidism) and lithium (can induce hypothyroidism or goiter).
Sources: Textbook of Family Medicine, 9e (Block 12) | Mulholland and Greenfield's Surgery, 7e (Block 14)
Pharmacology anti hypoglycemic agents
Reading File
Finding Sources
Finding Sources
Searching the Web
antihyperglycemic agents pharmacology classification mechanism of action 2024
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from Lippincott Pharmacology. Let me compile the full answer.
Pharmacology of Antihyperglycemic (Antidiabetic) Agents
Note: The term "antihyperglycemic agents" is more precise - these drugs lower blood glucose in diabetes. They are classified based on their mechanism of action.
Classification Overview
| Class | Examples | Route | Primary Use |
|---|---|---|---|
| Biguanides | Metformin | Oral | Type 2 DM (first-line) |
| Sulfonylureas | Glyburide, Glipizide, Glimepiride | Oral | Type 2 DM |
| Meglitinides (Glinides) | Repaglinide, Nateglinide | Oral | Type 2 DM (postprandial) |
| Thiazolidinediones (TZDs) | Pioglitazone, Rosiglitazone | Oral | Type 2 DM |
| Alpha-glucosidase inhibitors | Acarbose, Miglitol | Oral | Type 2 DM |
| DPP-4 Inhibitors (Gliptins) | Sitagliptin, Saxagliptin | Oral | Type 2 DM |
| SGLT-2 Inhibitors | Canagliflozin, Empagliflozin, Dapagliflozin | Oral | Type 2 DM + CVD/CKD |
| GLP-1 Receptor Agonists | Semaglutide, Liraglutide, Exenatide | Injectable (oral for semaglutide) | Type 2 DM + CVD |
| Amylin Analog | Pramlintide | Injectable | Adjunct in T1 & T2 DM |
| Insulin | Multiple types | Injectable | T1 DM + T2 DM |
1. Biguanides - Metformin
Metformin is the preferred first-line agent for type 2 diabetes. It is initiated at diagnosis.
Mechanism of Action:
- Primary: Reduces hepatic gluconeogenesis (targets excess fasting glucose)
- Slows intestinal absorption of glucose
- Improves peripheral insulin sensitivity (reduces insulin resistance)
- Does not stimulate insulin secretion - so hypoglycemia risk is very low when used alone
Pharmacokinetics: Well absorbed orally; not protein-bound; not metabolized; excreted unchanged by kidneys.
Adverse Effects:
- GI: Diarrhea, nausea, vomiting (minimize by slow dose titration and giving with meals)
- Weight loss / decreased appetite (beneficial in obese patients)
- Lactic acidosis - rare but serious; risk increases in renal impairment, acute heart failure, hepatic failure, and contrast dye use
Contraindications: Severe renal impairment (eGFR <30), acute heart failure, hepatic failure
Additional uses: Polycystic ovary syndrome (PCOS), prediabetes prevention
2. Sulfonylureas
Second-generation agents: Glyburide, Glipizide, Glimepiride
Mechanism of Action:
- Block ATP-sensitive K⁺ channels on pancreatic β-cells
- This causes membrane depolarization → Ca²⁺ influx → exocytosis of insulin
- Classified as insulin secretagogues
- Additional minor effects: reduce hepatic glucose production, increase peripheral insulin sensitivity
Pharmacokinetics: Oral; protein-bound; metabolized by liver; excreted in urine and feces; duration 12-24 hours.
Adverse Effects:
- Hypoglycemia (most important - due to non-glucose-dependent insulin release)
- Weight gain
- Hyperinsulinemia
- Use with caution in renal/hepatic insufficiency (accumulation risk)
- Glyburide is avoided in elderly and renal impairment - glipizide and glimepiride are safer alternatives
3. Meglitinides (Glinides)
Agents: Repaglinide, Nateglinide
Mechanism: Similar to sulfonylureas - stimulate insulin secretion from β-cells, but with rapid onset and short duration of action. Specifically effective at controlling postprandial glucose (post-meal glucose spikes).
Important: Must be taken before each meal. Do NOT combine with sulfonylureas (overlapping mechanism, serious hypoglycemia risk).
Pharmacokinetics:
- Repaglinide: metabolized by CYP2C8/CYP3A4; excreted in feces
- Nateglinide: metabolized by CYP2C9/CYP3A4; excreted in urine
Adverse effects: Hypoglycemia, weight gain (less than sulfonylureas)
4. Thiazolidinediones (TZDs / Glitazones)
Agents: Pioglitazone, Rosiglitazone
Mechanism: Activate PPAR-γ (peroxisome proliferator-activated receptor gamma) nuclear receptors → increase transcription of genes involved in glucose and lipid metabolism → reduce insulin resistance in adipose tissue, muscle, and liver.
Adverse Effects:
- Weight gain and fluid retention (edema)
- Risk of heart failure (contraindicated in NYHA class III/IV)
- Bone fractures (reduced bone density, especially in women)
- Rosiglitazone: concerns about increased myocardial infarction risk (heavily restricted)
- Bladder cancer risk (pioglitazone - avoid in bladder cancer patients)
- Slow onset - can take weeks to reach full effect
5. Alpha-Glucosidase Inhibitors
Agents: Acarbose, Miglitol
Mechanism: Inhibit alpha-glucosidase enzymes in the intestinal brush border → delay digestion and absorption of complex carbohydrates → blunt postprandial glucose rise
Adverse Effects: Mainly GI - flatulence, bloating, diarrhea (due to undigested carbohydrates in colon)
Note: Do NOT cause hypoglycemia when used alone. If hypoglycemia occurs in combination therapy, treat with glucose (dextrose), NOT sucrose (since sucrase is also inhibited).
6. DPP-4 Inhibitors (Gliptins)
Agents: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
Mechanism:
- Inhibit dipeptidyl peptidase-4 (DPP-4) enzyme, which normally degrades incretins (GLP-1, GIP)
- By inhibiting DPP-4, they prolong the action of endogenous GLP-1 and GIP
- Result: Increased glucose-dependent insulin secretion and suppressed glucagon
Adverse Effects: Generally well-tolerated; may increase risk of upper respiratory tract infections, pancreatitis (rare), and joint pain. Saxagliptin may increase risk of heart failure hospitalization.
7. SGLT-2 Inhibitors (Gliflozins)
Agents: Canagliflozin, Empagliflozin, Dapagliflozin, Ertugliflozin
Mechanism: Inhibit sodium-glucose cotransporter 2 (SGLT-2) in the proximal renal tubule → block renal glucose reabsorption → increase urinary glucose excretion (glycosuria) → lower blood glucose independently of insulin.
Key Benefits beyond glucose control:
- Reduce cardiovascular mortality and major adverse cardiac events
- Reduce progression of chronic kidney disease
- Reduce heart failure hospitalization
Adverse Effects:
- Urinary tract infections (UTI) and genital mycotic infections (due to glycosuria)
- Euglycemic diabetic ketoacidosis (rare but serious - occurs even with near-normal blood glucose)
- Volume depletion / hypotension
- Fournier's gangrene (necrotizing fasciitis of perineum - rare)
- Increased risk of amputation (canagliflozin)
8. GLP-1 Receptor Agonists (Incretin Mimetics)
Agents: Semaglutide, Liraglutide, Dulaglutide, Exenatide, Lixisenatide
Mechanism:
- Mimic the action of GLP-1 (glucagon-like peptide-1), an incretin hormone normally released from the gut after meals
- Stimulate glucose-dependent insulin secretion from β-cells
- Suppress glucagon secretion
- Delay gastric emptying (reduces postprandial glucose)
- Promote satiety and reduce appetite → significant weight loss
Key Benefits:
- Dulaglutide, liraglutide, and semaglutide demonstrated cardiovascular mortality reduction
- Significant weight loss (semaglutide now widely used for obesity as well)
Adverse Effects: Nausea, vomiting, diarrhea; risk of pancreatitis; contraindicated in personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
9. Amylin Analog - Pramlintide
Mechanism: Synthetic analog of amylin (co-secreted with insulin from β-cells):
- Delays gastric emptying
- Decreases postprandial glucagon
- Increases satiety
Use: Adjunct to mealtime insulin in type 1 and type 2 diabetes.
Important: When starting pramlintide, reduce mealtime insulin dose by 50% to avoid severe hypoglycemia. Do not mix with insulin in the same syringe.
Contraindications: Gastroparesis, hypoglycemic unawareness.
10. Insulin
Used in all type 1 diabetes and in type 2 diabetes when oral agents are insufficient.
| Type | Examples | Onset | Duration | Use |
|---|---|---|---|---|
| Rapid-acting | Lispro, Aspart, Glulisine | 5-15 min | 4-6 h | Mealtime control |
| Short-acting | Regular insulin | 30-60 min | 6-10 h | Mealtime, IV use |
| Intermediate | NPH insulin | 1-2 h | 12-18 h | Basal coverage |
| Long-acting | Glargine, Detemir, Degludec | 1-2 h | 20-24+ h | Basal (once daily) |
Adverse effects: Hypoglycemia, weight gain, lipodystrophy at injection sites.
Treatment Algorithm for Type 2 Diabetes
- Lifestyle modification + Metformin (at diagnosis)
- If A1C target not met, add a second agent based on:
- CVD or ASCVD present → GLP-1 RA or SGLT-2 inhibitor
- Heart failure (HFrEF) → SGLT-2 inhibitor preferred
- Chronic kidney disease → SGLT-2 inhibitor or GLP-1 RA
- Need to minimize cost → Sulfonylurea or TZD
- Need to minimize hypoglycemia → DPP-4i, GLP-1 RA, SGLT-2i, or TZD
- Need to minimize weight gain → GLP-1 RA or SGLT-2i
- Combination oral agents ± injectable GLP-1 RA ± insulin for refractory cases
Source: Lippincott Illustrated Reviews: Pharmacology (Chapter 24) | Textbook of Family Medicine, 9e
From kd tripathi book oral hypoglycemic agents
Finding Sources
Finding Sources
KD Tripathi's Essentials of Medical Pharmacology is not available in this textbook library. The library only has three pharmacology books: Goodman & Gilman's, Katzung's, and Lippincott's.
I can offer two options:
- Answer from Katzung or Goodman & Gilman - both are internationally recognized pharmacology references covering oral hypoglycemic agents in similar depth to KD Tripathi.
- Answer from Lippincott Illustrated Reviews Pharmacology - which I already searched in detail in the previous response.
The content on oral hypoglycemic agents in KD Tripathi follows the same pharmacological framework as these standard texts (sulfonylureas, biguanides, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonists). The classification, mechanisms, adverse effects, and drug interactions are the same across all these references since they are based on the same pharmacological science.
Would you like me to pull the oral hypoglycemic agents chapter from Katzung or Goodman & Gilman instead? These are the gold-standard pharmacology references available in the library and cover the topic comprehensively.
This is a shared conversation. Sign in to Orris to start your own chat.